(Q36832113)

16 August 2017

1 reference

title

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia (English)

1 reference

16 August 2017

0 references

1 reference

L Alinari

1

1 reference

16 August 2017

R Lapalombella

2

1 reference

16 August 2017

L Andritsos

3

1 reference

16 August 2017

R A Baiocchi

4

1 reference

16 August 2017

T S Lin

5

1 reference

16 August 2017

J C Byrd

6

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

26

1 reference

16 August 2017

25

1 reference

16 August 2017

3644-3653

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210380

16 August 2017

0 references

cites work

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

CD20-mediated apoptosis: signalling through lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Campath-1H monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Rafts: a simple way to control apoptosis by subcellular redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

The CD52 antigen and development of the CAMPATH antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Strategies in the management of alemtuzumab-related side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Monoclonal antibody therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

The CAMPATH-1 antigen (CDw52)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Humanised monoclonal antibody therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210380

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210380

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference